At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 66 enrolled
Drug / intervention
CTP-543 +1 moredrug
Likely dose
CTP-543 12 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Parallel-Group Study to Evaluate the Efficacy and Tolerability of Two Dosing Regimens of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
In Brief
A Phase 2 clinical trial evaluating CTP-543 and CTP-543 Matching Placebo for Alopecia Areata. Completed, enrolled 66 participants across 12 sites in 2 countries.
Detailed Summary
This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia Areata
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartMay 2019
Primary CompletionApr 2020
TodayJul 2026
First PostedMay 8, 2019
Enrollment StartMay 24, 2019
Primary CompletionApr 10, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.1 years ago
Interventions
CTP-543drug
Administered as 12 mg tablets.
CTP-543 Matching Placebodrug
Administered as tablets to aid treatment masking.